Integra LifeSciences Holdings Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Integra LifeSciences Holdings Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.8 times its market value (net debt). Lower than 96% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Higher than 69% of Healthcare companies in United States.
Cash Locked Ratio
$41For every $100 of sales, $41 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $31 tied up three years earlier.
More money tied up than 83% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +5% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+5% / -7%In 3 years sales changed by +5% while total assets changed by -7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.4×Debt due within a year is covered 0.4 times by its yearly operating cash.
Higher than 70% of Healthcare companies in United States.
Cash Cushion Ratio
1.8× debtDebt, after subtracting cash, is 1.8 times its market value (net debt).
Lower than 96% of Healthcare companies in United States.
Tangible Assets Ratio
51%Of every $100 the company owns, $51 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 78% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 91% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Integra LifeSciences Holdings Corporation owes $0.71 for every $1 it owns. Integra LifeSciences Holdings Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
72.5Investors pay $72.5 for every $1 of Integra LifeSciences Holdings Corporation's yearly profit, higher than 85% of Healthcare companies in United States.
P/B ratio
0.92The share price is 0.92 times Integra LifeSciences Holdings Corporation's book value per share, lower than 80% of Healthcare companies in United States.
Market cap
$959 MThe total market value of all of Integra LifeSciences Holdings Corporation's shares at today's price (share price × number of shares), larger than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$1.0 BWhat Integra LifeSciences Holdings Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$13.42Net worth divided by the number of shares. The share price of $12.33 is 0.9 times this, which is the P/B above.
Owes vs Owns
0.71×Integra LifeSciences Holdings Corporation owes $0.71 for every $1 it owns (moderate), higher than 72% of Healthcare companies in United States.
Dividend yield
NoneIntegra LifeSciences Holdings Corporation does not currently pay a dividend.
Revenue growth
+2%Revenue rose 2% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Profit growth
LossIntegra LifeSciences Holdings Corporation made a loss in each of the last two years.
Profit margin
-31.6%Integra LifeSciences Holdings Corporation lost $32 for every $100 of revenue.
Interest cover
0.2×Integra LifeSciences Holdings Corporation's operating profit covered its interest costs 0.2 times in the year to Dec 2025.
Cash vs debt
Net debtIntegra LifeSciences Holdings Corporation had $1.8 B more debt than cash (net debt) at Dec 2025.
Questions
What is Integra LifeSciences Holdings Corporation's P/E ratio?
Investors pay $72.5 for every $1 of Integra LifeSciences Holdings Corporation's yearly profit, higher than 85% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Integra LifeSciences Holdings Corporation: $959 M ÷ $1.0 B (30 Jun 2026) = 0.9.
How much does Integra LifeSciences Holdings Corporation owe compared with what it owns?
Integra LifeSciences Holdings Corporation owes $0.71 for every $1 it owns (moderate), higher than 72% of Healthcare companies in United States.
Does Integra LifeSciences Holdings Corporation pay a dividend?
No. Integra LifeSciences Holdings Corporation does not currently pay a dividend.
Is Integra LifeSciences Holdings Corporation's revenue growing?
Revenue rose 2% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.